{"id":"prostacyclin","rwe":[],"tags":[],"safety":{"commonSideEffects":[],"contraindications":["Blood coagulation disorder","Chronic heart failure","Pulmonary edema"]},"trials":[],"_chembl":null,"aliases":["epoprostenol sodium, Flolan","inhaled flolan","epoprostenol","inhaled PGI2","prostacyclin epoprostenol (PGIA) (Flolan®, Glaxo-Wellcome)"],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:35:30.281229","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=prostacyclin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:16:38.072845+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Prostacyclin","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:16:46.145591+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:16:51.853191+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:16:44.640843+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=prostacyclin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:16:45.011160+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1139/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:16:45.724406+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Prostacyclin, marketed by United Therapeutics, is currently positioned in the allergic rhinitis market. The drug's key strength lies in its unique mechanism of action, which differentiates it from other treatments. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.","ecosystem":[],"mechanism":{"target":"P2Y purinoceptor 12, Prostacyclin receptor, Prostaglandin E2 receptor EP1 subtype","modality":"Small Molecule"},"_scrapedAt":"2026-03-28T00:03:15.779Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Prostacyclin","title":"Prostacyclin","extract":"Prostacyclin (also called prostaglandin I2 or PGI2) is a prostaglandin member of the eicosanoid family of lipid molecules. It inhibits platelet activation and is also an effective vasodilator."},"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:16:51.853300+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Allergic rhinitis","diseaseId":"allergic-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Common cold","diseaseId":"common-cold","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Cough","diseaseId":"cough","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nasal congestion","diseaseId":"nasal-congestion","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nasal discharge","diseaseId":"nasal-discharge","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pulmonary arterial hypertension","diseaseId":"pulmonary-arterial-hypertension","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pulmonary hypertension","diseaseId":"pulmonary-hypertension","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rhinitis","diseaseId":"rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["sideEffects","modality→Small Molecule"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03626688","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2018-08-30","conditions":"PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension","enrollment":687},{"nctId":"NCT07450469","phase":"","title":"Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude","status":"NOT_YET_RECRUITING","sponsor":"Institute of Mountain Emergency Medicine","startDate":"2026-05","conditions":"Frostbite, Altitude, Field Physician Care","enrollment":10},{"nctId":"NCT07453030","phase":"","title":"Long-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Caio Júlio César dos Santos Fernandes","startDate":"2026-03-01","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":30},{"nctId":"NCT06969573","phase":"PHASE2","title":"Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2025-06-05","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":20},{"nctId":"NCT03683186","phase":"PHASE3","title":"A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension","status":"ENROLLING_BY_INVITATION","sponsor":"United Therapeutics","startDate":"2019-09-23","conditions":"PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension","enrollment":1000},{"nctId":"NCT07424378","phase":"PHASE4","title":"Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-02","conditions":"Frostbite","enrollment":66},{"nctId":"NCT07356375","phase":"","title":"Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-01","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":32},{"nctId":"NCT07356778","phase":"PHASE4","title":"A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy","status":"RECRUITING","sponsor":"Kazuya Hosokawa","startDate":"2025-10-07","conditions":"Eisenmenger Syndrome, Pulmonary Arterial Hypertension of Congenital Heart Disease","enrollment":36},{"nctId":"NCT00582478","phase":"","title":"Investigating Mechanisms to Explain Age Associated Differences in Quality of Life Among Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2001-10","conditions":"Breast Cancer","enrollment":650},{"nctId":"NCT06664801","phase":"PHASE2","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-14","conditions":"Pulmonary Arterial Hypertension","enrollment":164},{"nctId":"NCT06925750","phase":"PHASE2","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-12","conditions":"Pulmonary Arterial Hypertension","enrollment":130},{"nctId":"NCT07263958","phase":"NA","title":"Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD)","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-12-10","conditions":"Pulmnary Hypertension, COPD, Pulmonary Hypertension Secondary to Lung Disease and/or Hypoxia","enrollment":15},{"nctId":"NCT05450328","phase":"PHASE2","title":"Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation","status":"NOT_YET_RECRUITING","sponsor":"Montreal Heart Institute","startDate":"2025-11-01","conditions":"Right Heart Failure, Right Ventricular Dysfunction","enrollment":141},{"nctId":"NCT07116681","phase":"EARLY_PHASE1","title":"Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-10-01","conditions":"Pulmonary Hypertension","enrollment":8},{"nctId":"NCT01347216","phase":"","title":"COMPERA / COMPERA-KIDS","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2007-07-01","conditions":"Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)","enrollment":14000},{"nctId":"NCT06319274","phase":"PHASE2","title":"Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure","status":"RECRUITING","sponsor":"Pär Johansson","startDate":"2024-04-15","conditions":"Acute Respiratory Failure, Endothelial Dysfunction, Pulmonary Infection","enrollment":450},{"nctId":"NCT04452669","phase":"PHASE2","title":"VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation","status":"COMPLETED","sponsor":"Aerogen Pharma Limited","startDate":"2020-09-15","conditions":"COVID-19","enrollment":11},{"nctId":"NCT03122730","phase":"PHASE2","title":"VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB","status":"COMPLETED","sponsor":"Aerogen Pharma Limited","startDate":"2017-08-23","conditions":"Pulmonary Hypertension","enrollment":17},{"nctId":"NCT05629052","phase":"","title":"TrEatment Approach in the Multimodal Era Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"International CTEPH Association","startDate":"2023-04-12","conditions":"Chronic Thromboembolic Pulmonary Hypertension, CTEPH","enrollment":1000},{"nctId":"NCT02276872","phase":"PHASE2","title":"Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2014-12-18","conditions":"PAH","enrollment":32},{"nctId":"NCT05427162","phase":"PHASE1","title":"A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist","status":"COMPLETED","sponsor":"Actelion","startDate":"2022-06-21","conditions":"Pulmonary Arterial Hypertension","enrollment":88},{"nctId":"NCT03045029","phase":"","title":"ADAPT - A Patient Registry of the Real-world Use of Orenitram®","status":"ACTIVE_NOT_RECRUITING","sponsor":"United Therapeutics","startDate":"2017-07-18","conditions":"Pulmonary Arterial Hypertension","enrollment":300},{"nctId":"NCT06196801","phase":"","title":"Efficacy of Triple-Combination Therapy in Severe PAH-CHD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2022-06-17","conditions":"Congenital Heart Disease, Pulmonary Arterial Hypertension","enrollment":80},{"nctId":"NCT01470144","phase":"PHASE3","title":"Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-06-01","conditions":"Pulmonary Arterial Hypertension","enrollment":41},{"nctId":"NCT01105091","phase":"PHASE4","title":"Epoprostenol for Injection in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2010-03","conditions":"Pulmonary Arterial Hypertension","enrollment":30},{"nctId":"NCT03992755","phase":"PHASE3","title":"Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil","status":"ACTIVE_NOT_RECRUITING","sponsor":"Liquidia Technologies, Inc.","startDate":"2019-07-18","conditions":"Primary Pulmonary Hypertension","enrollment":92},{"nctId":"NCT05060315","phase":"","title":"Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin","status":"TERMINATED","sponsor":"United Therapeutics","startDate":"2023-07-05","conditions":"Pulmonary Arterial Hypertension","enrollment":9},{"nctId":"NCT06753981","phase":"","title":"Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study","status":"RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2024-12-10","conditions":"Arterial Pulmonary Hypertension (PAH)","enrollment":48},{"nctId":"NCT05825417","phase":"PHASE4","title":"Pulmonary Hypertension: Intensification and Personalisation of Combination Rx","status":"RECRUITING","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2023-06-14","conditions":"Pulmonary Arterial Hypertension","enrollment":40},{"nctId":"NCT03451591","phase":"PHASE2, PHASE3","title":"LACunar Intervention (LACI-2) Trial-2","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2018-01-08","conditions":"Cerebral Small Vessel Diseases, Stroke, Lacunar","enrollment":363},{"nctId":"NCT03950739","phase":"PHASE1","title":"Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2019-09-17","conditions":"Pulmonary Arterial Hypertension","enrollment":51},{"nctId":"NCT02170519","phase":"PHASE4","title":"Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide","status":"TERMINATED","sponsor":"Duke University","startDate":"2006-09","conditions":"Pulmonary Hypertension","enrollment":27},{"nctId":"NCT04576988","phase":"PHASE3","title":"A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2021-01-25","conditions":"Pulmonary Arterial Hypertension","enrollment":324},{"nctId":"NCT03738150","phase":"PHASE2","title":"A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2019-04-19","conditions":"Pulmonary Arterial Hypertension","enrollment":21},{"nctId":"NCT02251041","phase":"PHASE2","title":"Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2014-09","conditions":"Reperfusion Injury","enrollment":143},{"nctId":"NCT04231084","phase":"PHASE4","title":"Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-01-15","conditions":"Pulmonary Hypertension","enrollment":115},{"nctId":"NCT03399604","phase":"PHASE3","title":"Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil","status":"COMPLETED","sponsor":"Liquidia Technologies, Inc.","startDate":"2018-01-02","conditions":"Primary Pulmonary Hypertension","enrollment":121},{"nctId":"NCT06429579","phase":"NA","title":"Potts-shunt for the Treatment of Pediatric Patients With Severe Pulmonary Hypertension","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2024-04-23","conditions":"Pulmonary Artery Hypertension","enrollment":120},{"nctId":"NCT03903939","phase":"PHASE2","title":"Infusion of Prostacyclin vs Placebo for 72-hours in Trauma Patients With Haemorrhagic Shock Suffering From Organ Failure","status":"COMPLETED","sponsor":"Pär Johansson","startDate":"2019-05-22","conditions":"Multi Organ Failure","enrollment":228},{"nctId":"NCT04123444","phase":"PHASE2, PHASE3","title":"Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure","status":"COMPLETED","sponsor":"Jakob Stensballe, MD, PhD","startDate":"2019-10-30","conditions":"Septic Shock","enrollment":279},{"nctId":"NCT04420741","phase":"PHASE2","title":"Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure","status":"COMPLETED","sponsor":"Pär Johansson","startDate":"2020-06-15","conditions":"COVID-19, Respiratory Failure","enrollment":80},{"nctId":"NCT06317805","phase":"PHASE4","title":"Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients","status":"RECRUITING","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2023-12-06","conditions":"Pulmonary Arterial Hypertension","enrollment":110},{"nctId":"NCT02261883","phase":"PHASE2","title":"Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn","status":"TERMINATED","sponsor":"United Therapeutics","startDate":"2015-07-29","conditions":"Persistent Pulmonary Hypertension of the Newborn","enrollment":42},{"nctId":"NCT05311072","phase":"","title":"Change-a Multi-center Chronic Thromboembolic Pulmonary Hypertension （CTEPH） Database in China","status":"RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2015-10-01","conditions":"Chronic Thromboembolic Pulmonary Hypertension","enrollment":1500},{"nctId":"NCT00439946","phase":"PHASE4","title":"Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH","status":"TERMINATED","sponsor":"United Therapeutics","startDate":"2007-02","conditions":"Pulmonary Arterial Hypertension","enrollment":8},{"nctId":"NCT00643604","phase":"PHASE4","title":"Rapid Switch From Flolan to Remodulin in the Outpatient Clinic","status":"TERMINATED","sponsor":"United Therapeutics","startDate":"2008-03","conditions":"Hypertension, Pulmonary","enrollment":7},{"nctId":"NCT00775463","phase":"PHASE2","title":"Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2009-05","conditions":"Systemic Sclerosis, Scleroderma","enrollment":148},{"nctId":"NCT01884038","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients","status":"WITHDRAWN","sponsor":"United Therapeutics","startDate":"2008-06","conditions":"Liver Transplant","enrollment":""},{"nctId":"NCT05099367","phase":"NA","title":"Prostacyclin (PGI2) Pathway to Enhance Wound Healing in Diabetic Foot Ulcers","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2021-10-01","conditions":"Diabetes Mellitus, Type 2, Diabetic Foot","enrollment":60},{"nctId":"NCT04084678","phase":"PHASE3","title":"A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH","status":"TERMINATED","sponsor":"United Therapeutics","startDate":"2021-01-20","conditions":"PAH, Pulmonary Hypertension, Hypertension","enrollment":10},{"nctId":"NCT03367312","phase":"PHASE2","title":"Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI","status":"COMPLETED","sponsor":"Bastiaan Driehuys","startDate":"2018-03-29","conditions":"Pulmonary Vascular Disease","enrollment":11},{"nctId":"NCT04005469","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation","status":"RECRUITING","sponsor":"Rhode Island Hospital","startDate":"2020-11-13","conditions":"Ischemia Reperfusion Injury, Delayed Graft Function","enrollment":20},{"nctId":"NCT03496207","phase":"PHASE2","title":"A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2018-06-13","conditions":"Pulmonary Arterial Hypertension","enrollment":106},{"nctId":"NCT05600218","phase":"","title":"RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists","status":"UNKNOWN","sponsor":"Hospital Costa del Sol","startDate":"2021-06-01","conditions":"Pulmonary Arterial Hypertension","enrollment":60},{"nctId":"NCT02565030","phase":"","title":"Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2015-02","conditions":"Chronic Thromboembolic Pulmonary Hypertension, Idiopathic Pulmonary Arterial Hypertension","enrollment":1200},{"nctId":"NCT03884465","phase":"PHASE2","title":"Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil","status":"TERMINATED","sponsor":"Liquidia Technologies, Inc.","startDate":"2019-11-11","conditions":"Pulmonary Arterial Hypertension","enrollment":15},{"nctId":"NCT02685618","phase":"PHASE2","title":"Endothelial Dysfunction in Resuscitated Cardiac Arrest","status":"COMPLETED","sponsor":"Pär Johansson","startDate":"2016-02","conditions":"Cardiac Arrest","enrollment":50},{"nctId":"NCT01528943","phase":"PHASE1","title":"Effect of Prostacyclin on Haemostasis in Abdominal Surgery","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2012-03","conditions":"Surgery","enrollment":40},{"nctId":"NCT00159861","phase":"PHASE3","title":"The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-07","conditions":"Pulmonary Hypertension","enrollment":267},{"nctId":"NCT01966302","phase":"PHASE2","title":"Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2013-11","conditions":"Pulmonary Arterial Hypertension","enrollment":1},{"nctId":"NCT04594629","phase":"PHASE1","title":"PGI2 Versus Nitroglycerine for Management of Pulmonary Hypertension After Valve Surgeries","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2020-11","conditions":"Pulmonary Hypertension","enrollment":120},{"nctId":"NCT04589390","phase":"PHASE2","title":"Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-10-15","conditions":"Pulmonary Hypertension, Schistosomiasis","enrollment":20},{"nctId":"NCT04578223","phase":"","title":"Platelet Reactivity and Treatment With Prostacyclin Analogues in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2017-07-05","conditions":"Pulmonary Hypertension","enrollment":80},{"nctId":"NCT03657095","phase":"PHASE3","title":"A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Lung Biotechnology PBC","startDate":"2018-12-10","conditions":"Pulmonary Arterial Hypertension","enrollment":112},{"nctId":"NCT00703989","phase":"NA","title":"Reactive Oxygen Species in the Pathogenesis of Diabetic Complications","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2005-02","conditions":"Type 1 Diabetes","enrollment":21},{"nctId":"NCT02220335","phase":"NA","title":"Pulmonary Arterial Denervation in Patients With Pulmonary Hypertension Associated With the Left Heart Failure","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2014-08-08","conditions":"Pulmonary Hypertension","enrollment":98},{"nctId":"NCT03380325","phase":"NA","title":"The Effect of Iloprost on Capillary Recruitment and Insulin Sensitivity in Type 2 Diabetes","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2016-05-11","conditions":"Diabetes Mellitus, Type 2, Insulin Sensitivity/Resistance","enrollment":15},{"nctId":"NCT02748265","phase":"PHASE4","title":"Nebulized Epoprostenol (FLOLAN) and Phenylephrine on One Lung Ventilation (OLV)","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2016-03","conditions":"Oxygenation During One Lung Ventilation","enrollment":8},{"nctId":"NCT01470703","phase":"NA","title":"Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-12-08","conditions":"Acute Respiratory Distress Syndrome (ARDS)","enrollment":249},{"nctId":"NCT01370096","phase":"PHASE2","title":"Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2012-02","conditions":"Pulmonary Hypertension","enrollment":3},{"nctId":"NCT01389206","phase":"","title":"Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-06-01","conditions":"Pulmonary Arterial Hypertension","enrollment":797},{"nctId":"NCT00524433","phase":"PHASE3","title":"Tezosentan in the Treatment of Acute Heart Failure","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2003-04","conditions":"Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure","enrollment":713},{"nctId":"NCT00525707","phase":"PHASE3","title":"Tezosentan in Acute Heart Failure","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2003-04","conditions":"Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure","enrollment":735},{"nctId":"NCT00458276","phase":"PHASE3","title":"Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery","status":"TERMINATED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2007-04","conditions":"Heart Diseases, Hypertension, Pulmonary","enrollment":274},{"nctId":"NCT01094067","phase":"PHASE2","title":"Tezosentan in Patients With Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2010-09-01","conditions":"Pulmonary Arterial Hypertension","enrollment":2},{"nctId":"NCT01077297","phase":"PHASE2","title":"Tezosentan in Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2010-08","conditions":"Pulmonary Arterial Hypertension","enrollment":3},{"nctId":"NCT01462565","phase":"PHASE4","title":"Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-01","conditions":"Hypertension, Pulmonary","enrollment":16},{"nctId":"NCT01717209","phase":"PHASE4","title":"Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement","status":"COMPLETED","sponsor":"Stanford University","startDate":"2012-10","conditions":"Heart Failure","enrollment":14},{"nctId":"NCT01980979","phase":"NA","title":"Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2013-11","conditions":"Congenital Heart Disease","enrollment":""},{"nctId":"NCT01268553","phase":"PHASE4","title":"Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2010-08","conditions":"Pulmonary Arterial Hypertension","enrollment":6},{"nctId":"NCT01387191","phase":"","title":"Drug Use Investigation for FLOLAN (Epoprostenol) Injection 0.5mg・1.5mg","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-08","conditions":"Cardiovascular Disease","enrollment":748},{"nctId":"NCT00748371","phase":"PHASE4","title":"Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2004-06","conditions":"Platelet Aggregation","enrollment":51},{"nctId":"NCT02705807","phase":"PHASE4","title":"Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05","conditions":"Cardiovascular Disease","enrollment":10},{"nctId":"NCT01941225","phase":"PHASE2","title":"Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2013-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":24},{"nctId":"NCT02189122","phase":"NA","title":"Comparative Effects of Aspirin and NHP-544C","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-07","conditions":"Healthy","enrollment":61},{"nctId":"NCT01040819","phase":"PHASE4","title":"Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2010-02","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT00722254","phase":"","title":"Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder","status":"TERMINATED","sponsor":"University of Utah","startDate":"2006-06","conditions":"Primary Myelofibrosis, Primary Pulmonary Hypertension, Secondary Myelofibrosis","enrollment":15},{"nctId":"NCT01266265","phase":"","title":"Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2010-12","conditions":"Pulmonary Arterial Hypertension","enrollment":1333},{"nctId":"NCT01061060","phase":"PHASE4","title":"The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-01","conditions":"Type 2 Diabetes Mellitus, Peripheral Microvascular Symptoms","enrollment":110},{"nctId":"NCT02480751","phase":"PHASE2","title":"TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)","status":"COMPLETED","sponsor":"Toray Industries, Inc","startDate":"2005-10","conditions":"Renal Insufficiency, Chronic","enrollment":113},{"nctId":"NCT01056835","phase":"PHASE3","title":"Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2009-06","conditions":"Chronic Allograft Nephropathy","enrollment":40},{"nctId":"NCT02077673","phase":"","title":"Gastric Microperfusion in Patients Undergoing Gastroesophageal Resections","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2013-12","conditions":"Gastroesophageal Junction Adenocarcinoma, Surgery","enrollment":50},{"nctId":"NCT01090037","phase":"PHASE2, PHASE3","title":"TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)","status":"COMPLETED","sponsor":"Toray Industries, Inc","startDate":"2010-03","conditions":"Chronic Renal Failure, Glomerular Disease, Nephrosclerosis","enrollment":892},{"nctId":"NCT01319045","phase":"NA","title":"Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2011-06","conditions":"Pulmonary Arterial Hypertension, Congenital Heart Disease, Eisenmenger's Syndrome","enrollment":5},{"nctId":"NCT01431716","phase":"PHASE3","title":"Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-03","conditions":"Pulmonary Arterial Hypertension","enrollment":42},{"nctId":"NCT01447095","phase":"PHASE2","title":"Effects of Prostacyclin Infusion on Cerebral Vessels and Metabolism in Patients With Subarachnoid Haemorrhage","status":"COMPLETED","sponsor":"Rune Rasmussen","startDate":"2011-10","conditions":"Subarachnoid Hemorrhage","enrollment":90},{"nctId":"NCT01329562","phase":"PHASE4","title":"CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet","status":"COMPLETED","sponsor":"Cady, Roger, M.D.","startDate":"2011-05","conditions":"Menstrual Migraine","enrollment":41},{"nctId":"NCT00494533","phase":"PHASE4","title":"Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"United Therapeutics","startDate":"2005-03","conditions":"Pulmonary Arterial Hypertension","enrollment":45},{"nctId":"NCT00058929","phase":"PHASE4","title":"A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2002-10","conditions":"Pulmonary Arterial Hypertension, Pulmonary Hypertension","enrollment":39},{"nctId":"NCT00373360","phase":"PHASE4","title":"Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2006-09","conditions":"Pulmonary Hypertension","enrollment":10}],"_emaApprovals":[],"_faersSignals":[{"count":31,"reaction":"DYSPNOEA"},{"count":25,"reaction":"DRUG INEFFECTIVE"},{"count":18,"reaction":"HEADACHE"},{"count":13,"reaction":"DIARRHOEA"},{"count":12,"reaction":"OFF LABEL USE"},{"count":11,"reaction":"PAIN IN EXTREMITY"},{"count":10,"reaction":"HYPOTENSION"},{"count":8,"reaction":"FATIGUE"},{"count":8,"reaction":"FLUSHING"},{"count":8,"reaction":"PULMONARY ARTERIAL HYPERTENSION"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1139"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":15112,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"prostacyclin","genericName":"prostacyclin","companyName":"United Therapeutics","companyId":"united-therapeutics","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:16:51.853300+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}